Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice

Brittany L. Mason, Sarah A. Thomas, Stafford L. Lightman, Carmine M. Pariante

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with depression can be reduced by antidepressants, which are thought to improve endogenous glucocorticoid-mediated negative feedback. A proportion of peripherally released glucocorticoids need to enter brain tissue, protected by the blood-brain barrier (BBB), in order to achieve this negative feedback effect at the level of the central nervous systems (CNS). The multidrug resistance transporter P-glycoprotein (P-gp) has been shown to actively transport glucocorticoid hormones and has been implicated in the regulation of glucocorticoid access to the CNS. Using an in situ brain/choroid plexus perfusion method, we tested the hypothesis that the antidepressant desipramine increases glucocorticoid accumulation in the mouse brain by inhibiting P-gp, following either chronic treatment (8 days, 20mg/kg/day, IP) or acute administration (20min brain perfusion in the presence of either 0.9μM or 10μM desipramine). Contrary to our hypothesis, chronic treatment with desipramine did not affect the accumulation of [ 3H]dexamethasone in any sample compared to saline-treated mice. Acute desipramine had limited and variable effects on glucocorticoid accumulation in the CNS, with accumulation of [ 3H]dexamethasone increased in the cerebellum, accumulation of [ 3H]cortisol reduced in the frontal cortex, hypothalamus, and cerebellum, and accumulation of [ 3H]corticosterone (the endogenous glucocorticoid in rodents) not affected. Overall, under the conditions tested, these results do not support the hypothesis that treatment with desipramine can inhibit P-gp at the BBB and subsequently increase the accumulation of glucocorticoids in the brain.

Original languageEnglish (US)
Pages (from-to)1351-1360
Number of pages10
JournalPsychoneuroendocrinology
Volume36
Issue number9
DOIs
StatePublished - Oct 1 2011

Fingerprint

Desipramine
P-Glycoprotein
Glucocorticoids
Brain
Central Nervous System
Therapeutics
Blood-Brain Barrier
Cerebellum
Dexamethasone
Antidepressive Agents
Perfusion
Choroid Plexus
Multiple Drug Resistance
Frontal Lobe
Corticosterone
Hypothalamus
Hydrocortisone
Rodentia
Hormones

Keywords

  • Antidepressants
  • Blood-brain barrier
  • Desipramine
  • Glucocorticoids
  • Hypothalamic-pituitary-adrenal (HPA) axis

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems

Cite this

Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice. / Mason, Brittany L.; Thomas, Sarah A.; Lightman, Stafford L.; Pariante, Carmine M.

In: Psychoneuroendocrinology, Vol. 36, No. 9, 01.10.2011, p. 1351-1360.

Research output: Contribution to journalArticle

Mason, Brittany L. ; Thomas, Sarah A. ; Lightman, Stafford L. ; Pariante, Carmine M. / Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice. In: Psychoneuroendocrinology. 2011 ; Vol. 36, No. 9. pp. 1351-1360.
@article{28c32922e784468ba03999876adb4311,
title = "Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice",
abstract = "Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with depression can be reduced by antidepressants, which are thought to improve endogenous glucocorticoid-mediated negative feedback. A proportion of peripherally released glucocorticoids need to enter brain tissue, protected by the blood-brain barrier (BBB), in order to achieve this negative feedback effect at the level of the central nervous systems (CNS). The multidrug resistance transporter P-glycoprotein (P-gp) has been shown to actively transport glucocorticoid hormones and has been implicated in the regulation of glucocorticoid access to the CNS. Using an in situ brain/choroid plexus perfusion method, we tested the hypothesis that the antidepressant desipramine increases glucocorticoid accumulation in the mouse brain by inhibiting P-gp, following either chronic treatment (8 days, 20mg/kg/day, IP) or acute administration (20min brain perfusion in the presence of either 0.9μM or 10μM desipramine). Contrary to our hypothesis, chronic treatment with desipramine did not affect the accumulation of [ 3H]dexamethasone in any sample compared to saline-treated mice. Acute desipramine had limited and variable effects on glucocorticoid accumulation in the CNS, with accumulation of [ 3H]dexamethasone increased in the cerebellum, accumulation of [ 3H]cortisol reduced in the frontal cortex, hypothalamus, and cerebellum, and accumulation of [ 3H]corticosterone (the endogenous glucocorticoid in rodents) not affected. Overall, under the conditions tested, these results do not support the hypothesis that treatment with desipramine can inhibit P-gp at the BBB and subsequently increase the accumulation of glucocorticoids in the brain.",
keywords = "Antidepressants, Blood-brain barrier, Desipramine, Glucocorticoids, Hypothalamic-pituitary-adrenal (HPA) axis",
author = "Mason, {Brittany L.} and Thomas, {Sarah A.} and Lightman, {Stafford L.} and Pariante, {Carmine M.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.psyneuen.2011.03.008",
language = "English (US)",
volume = "36",
pages = "1351--1360",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice

AU - Mason, Brittany L.

AU - Thomas, Sarah A.

AU - Lightman, Stafford L.

AU - Pariante, Carmine M.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with depression can be reduced by antidepressants, which are thought to improve endogenous glucocorticoid-mediated negative feedback. A proportion of peripherally released glucocorticoids need to enter brain tissue, protected by the blood-brain barrier (BBB), in order to achieve this negative feedback effect at the level of the central nervous systems (CNS). The multidrug resistance transporter P-glycoprotein (P-gp) has been shown to actively transport glucocorticoid hormones and has been implicated in the regulation of glucocorticoid access to the CNS. Using an in situ brain/choroid plexus perfusion method, we tested the hypothesis that the antidepressant desipramine increases glucocorticoid accumulation in the mouse brain by inhibiting P-gp, following either chronic treatment (8 days, 20mg/kg/day, IP) or acute administration (20min brain perfusion in the presence of either 0.9μM or 10μM desipramine). Contrary to our hypothesis, chronic treatment with desipramine did not affect the accumulation of [ 3H]dexamethasone in any sample compared to saline-treated mice. Acute desipramine had limited and variable effects on glucocorticoid accumulation in the CNS, with accumulation of [ 3H]dexamethasone increased in the cerebellum, accumulation of [ 3H]cortisol reduced in the frontal cortex, hypothalamus, and cerebellum, and accumulation of [ 3H]corticosterone (the endogenous glucocorticoid in rodents) not affected. Overall, under the conditions tested, these results do not support the hypothesis that treatment with desipramine can inhibit P-gp at the BBB and subsequently increase the accumulation of glucocorticoids in the brain.

AB - Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with depression can be reduced by antidepressants, which are thought to improve endogenous glucocorticoid-mediated negative feedback. A proportion of peripherally released glucocorticoids need to enter brain tissue, protected by the blood-brain barrier (BBB), in order to achieve this negative feedback effect at the level of the central nervous systems (CNS). The multidrug resistance transporter P-glycoprotein (P-gp) has been shown to actively transport glucocorticoid hormones and has been implicated in the regulation of glucocorticoid access to the CNS. Using an in situ brain/choroid plexus perfusion method, we tested the hypothesis that the antidepressant desipramine increases glucocorticoid accumulation in the mouse brain by inhibiting P-gp, following either chronic treatment (8 days, 20mg/kg/day, IP) or acute administration (20min brain perfusion in the presence of either 0.9μM or 10μM desipramine). Contrary to our hypothesis, chronic treatment with desipramine did not affect the accumulation of [ 3H]dexamethasone in any sample compared to saline-treated mice. Acute desipramine had limited and variable effects on glucocorticoid accumulation in the CNS, with accumulation of [ 3H]dexamethasone increased in the cerebellum, accumulation of [ 3H]cortisol reduced in the frontal cortex, hypothalamus, and cerebellum, and accumulation of [ 3H]corticosterone (the endogenous glucocorticoid in rodents) not affected. Overall, under the conditions tested, these results do not support the hypothesis that treatment with desipramine can inhibit P-gp at the BBB and subsequently increase the accumulation of glucocorticoids in the brain.

KW - Antidepressants

KW - Blood-brain barrier

KW - Desipramine

KW - Glucocorticoids

KW - Hypothalamic-pituitary-adrenal (HPA) axis

UR - http://www.scopus.com/inward/record.url?scp=80052731723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052731723&partnerID=8YFLogxK

U2 - 10.1016/j.psyneuen.2011.03.008

DO - 10.1016/j.psyneuen.2011.03.008

M3 - Article

VL - 36

SP - 1351

EP - 1360

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

IS - 9

ER -